Long-term mebendazole therapy may be parasitocidal in alveolar echinococcosis.
Long-term chemotherapy of human alveolar echinococcosis with benzimidazole compounds (mebendazole, albendazole) has been shown to be primarily parasitostatic, but its curative (parasitocidal) efficacy is debated. This article reports on a 67-year-old male patient with non-resectable alveolar echinococcosis of the liver who had been continuously treated for 13 years with mebendazole (approximately 45-48 mg/kg body weight per day) and who was closely monitored according to a specific protocol. At the age of 80 years the patient died of oesophageal variceal bleeding. During treatment the hepatic lesion had decreased markedly in size in association with progression of perifocal calcification. At autopsy, a well-demarcated, necrotic, partially calcified, parasite-induced lesion of the right liver lobe and secondary biliary cirrhosis were found. Remnants of parasite tissue obtained from the periphery of the lesion showed a small-cystic structure, but it was not viable, as evidenced by transplantation of tissue blocks to rodents. The case is suggestive for a parasitocidal efficacy of mebendazole treatment carried out for 13 years, and is discussed in context with conflicting literature data.
Ammann
R W
RW
Department of Medicine, University Hospital, University of Zurich, Switzerland.
Fleiner-Hoffmann
A
A
Grimm
F
F
Eckert
J
J
D000368:Aged; D000969:Antinematodal Agents / Q000627:therapeutic use*; D004444:Echinococcosis, Hepatic / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008463:Mebendazole / Q000627:therapeutic use*; D013997:Time Factors
D000969:Antinematodal Agents; D008463:Mebendazole